173 related articles for article (PubMed ID: 30338914)
1. MiR-17 family-mediated regulation of Pknox1 influences hepatic steatosis and insulin signaling.
Ye D; Lou G; Zhang T; Dong F; Liu Y
J Cell Mol Med; 2018 Dec; 22(12):6167-6175. PubMed ID: 30338914
[TBL] [Abstract][Full Text] [Related]
2. MiR-150 deficiency ameliorated hepatosteatosis and insulin resistance in nonalcoholic fatty liver disease via targeting CASP8 and FADD-like apoptosis regulator.
Zhuge B; Li G
Biochem Biophys Res Commun; 2017 Dec; 494(3-4):687-692. PubMed ID: 29107687
[TBL] [Abstract][Full Text] [Related]
3. Downregulation of miR-192 causes hepatic steatosis and lipid accumulation by inducing SREBF1: Novel mechanism for bisphenol A-triggered non-alcoholic fatty liver disease.
Lin Y; Ding D; Huang Q; Liu Q; Lu H; Lu Y; Chi Y; Sun X; Ye G; Zhu H; Wei J; Dong S
Biochim Biophys Acta Mol Cell Biol Lipids; 2017 Sep; 1862(9):869-882. PubMed ID: 28483554
[TBL] [Abstract][Full Text] [Related]
4. Dysregulation of microRNA-125a contributes to obesity-associated insulin resistance and dysregulates lipid metabolism in mice.
Liu R; Wang M; Li E; Yang Y; Li J; Chen S; Shen WJ; Azhar S; Guo Z; Hu Z
Biochim Biophys Acta Mol Cell Biol Lipids; 2020 May; 1865(5):158640. PubMed ID: 31988048
[TBL] [Abstract][Full Text] [Related]
5. Thrombospondin 1 improves hepatic steatosis in diet-induced insulin-resistant mice and is associated with hepatic fat content in humans.
Bai J; Xia M; Xue Y; Ma F; Cui A; Sun Y; Han Y; Xu X; Zhang F; Hu Z; Liu Z; Liu Y; Cai G; Su W; Sun X; Wu H; Yan H; Chang X; Hu X; Bian H; Xia P; Gao J; Li Y; Gao X
EBioMedicine; 2020 Jul; 57():102849. PubMed ID: 32580141
[TBL] [Abstract][Full Text] [Related]
6. Yunpi Heluo decoction attenuates insulin resistance by regulating liver miR-29a-3p in Zucker diabetic fatty rats.
Mao ZJ; Weng SY; Lin M; Chai KF
J Ethnopharmacol; 2019 Oct; 243():111966. PubMed ID: 31128151
[TBL] [Abstract][Full Text] [Related]
7. Downregulated microRNA-130b-5p prevents lipid accumulation and insulin resistance in a murine model of nonalcoholic fatty liver disease.
Liu X; Chen S; Zhang L
Am J Physiol Endocrinol Metab; 2020 Jul; 319(1):E34-E42. PubMed ID: 32228319
[TBL] [Abstract][Full Text] [Related]
8. The p66shc-mediated Regulation of Hepatocyte Senescence Influences Hepatic Steatosis in Nonalcoholic Fatty Liver Disease.
Zhang J; Li Y; Wang B; Luo Y; Shi J; Zhao B
Med Sci Monit; 2020 Mar; 26():e921887. PubMed ID: 32191680
[TBL] [Abstract][Full Text] [Related]
9. Overexpression of Hepassocin in Diabetic Patients with Nonalcoholic Fatty Liver Disease May Facilitate Increased Hepatic Lipid Accumulation.
Abdelmoemen G; Khodeir SA; Zaki AN; Kassab M; Abou-Saif S; Abd-Elsalam S
Endocr Metab Immune Disord Drug Targets; 2019; 19(2):185-188. PubMed ID: 30009716
[TBL] [Abstract][Full Text] [Related]
10. miR-3666 inhibits development of hepatic steatosis by negatively regulating PPARγ.
Mittal S; Inamdar S; Acharya J; Pekhale K; Kalamkar S; Boppana R; Ghaskadbi S
Biochim Biophys Acta Mol Cell Biol Lipids; 2020 Oct; 1865(10):158777. PubMed ID: 32755726
[TBL] [Abstract][Full Text] [Related]
11. MicroRNA-122 Inhibits Lipid Droplet Formation and Hepatic Triglyceride Accumulation via Yin Yang 1.
Wu GY; Rui C; Chen JQ; Sho E; Zhan SS; Yuan XW; Ding YT
Cell Physiol Biochem; 2017; 44(4):1651-1664. PubMed ID: 29216638
[TBL] [Abstract][Full Text] [Related]
12. MicroRNA-190b regulates lipid metabolism and insulin sensitivity by targeting IGF-1 and ADAMTS9 in non-alcoholic fatty liver disease.
Xu M; Zheng XM; Jiang F; Qiu WQ
J Cell Biochem; 2018 Jul; 119(7):5864-5874. PubMed ID: 29575055
[TBL] [Abstract][Full Text] [Related]
13. miR-188 promotes liver steatosis and insulin resistance via the autophagy pathway.
Liu Y; Zhou X; Xiao Y; Li C; Huang Y; Guo Q; Su T; Fu L; Luo L
J Endocrinol; 2020 Jun; 245(3):411-423. PubMed ID: 32252024
[TBL] [Abstract][Full Text] [Related]
14. miR-122 promotes hepatic lipogenesis via inhibiting the LKB1/AMPK pathway by targeting Sirt1 in non-alcoholic fatty liver disease.
Long JK; Dai W; Zheng YW; Zhao SP
Mol Med; 2019 Jun; 25(1):26. PubMed ID: 31195981
[TBL] [Abstract][Full Text] [Related]
15. microRNA-141 is associated with hepatic steatosis by downregulating the sirtuin1/AMP-activated protein kinase pathway in hepatocytes.
Yousefi Z; Nourbakhsh M; Abdolvahabi Z; Ghorbanhosseini SS; Hesari Z; Yarahmadi S; Ezzati-Mobasser S; Seiri P; Borji M; Meshkani R; Malek M
J Cell Physiol; 2020 Feb; 235(2):880-890. PubMed ID: 31256424
[TBL] [Abstract][Full Text] [Related]
16. Multiple MicroRNAs Ameliorate Hepatocyte Steatosis and Injury by Suppressing FABP1 Expression.
Wu YL; Zhu YB; Huang RD; Peng XE; Lin X
Cell Physiol Biochem; 2017; 44(6):2243-2255. PubMed ID: 29258109
[TBL] [Abstract][Full Text] [Related]
17. Aberrant hepatic microRNA expression in nonalcoholic fatty liver disease.
Feng YY; Xu XQ; Ji CB; Shi CM; Guo XR; Fu JF
Cell Physiol Biochem; 2014; 34(6):1983-97. PubMed ID: 25562147
[TBL] [Abstract][Full Text] [Related]
18. LncRNA-H19 promotes hepatic lipogenesis by directly regulating miR-130a/PPARγ axis in non-alcoholic fatty liver disease.
Liu J; Tang T; Wang GD; Liu B
Biosci Rep; 2019 Jul; 39(7):. PubMed ID: 31064820
[No Abstract] [Full Text] [Related]
19. Long noncoding RNA Mirt2 upregulates USP10 expression to suppress hepatic steatosis by sponging miR-34a-5p.
Zhang B; Li H; Li D; Sun H; Li M; Hu H
Gene; 2019 Jun; 700():139-148. PubMed ID: 30898698
[TBL] [Abstract][Full Text] [Related]
20. Degradation of PHLPP2 by KCTD17, via a Glucagon-Dependent Pathway, Promotes Hepatic Steatosis.
Kim K; Ryu D; Dongiovanni P; Ozcan L; Nayak S; Ueberheide B; Valenti L; Auwerx J; Pajvani UB
Gastroenterology; 2017 Dec; 153(6):1568-1580.e10. PubMed ID: 28859855
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
